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Abstract 
Nitric oxide (NO) was discovered as a biologically active molecule over two decades 
ago and it has since been recognised as one of the most versatile components of the 
immune system, with involvement in both cytotoxic and regulatory functions. It is a 
readily diffusible gas that has been established as a universal messenger, capable of 
mediating cell-cell communication throughout the body. It is involved in the 
pathogenesis and also the control of infectious diseases, autoimmunity, chronic 
degenerative diseases and tumours. This review will collate, contrast and compare 
recently published literature, to provide an up-to-date and contemporary overview of the 
substantial role that NO plays within the immune system.  
Introduction  
Nitric oxide is formed following enzyme activation of one of three NO synthase isoforms, 
converting the amino acid substrate L-arginine to citrulline. Two of the synthases are 
constitutively expressed within the body; endothelial NO synthase (eNOS) and neuronal 
NO synthase (nNOS) (Guzik et al 2003). Contrary to their given names, expression is 
not restricted to neurons or endothelial cells. nNOS is found in high amounts in the 
CNS, testes and skeletal muscle where it is involved (among other physiological 
functions) with endocrine regulation, platelet aggregation, neuromodulation and skeletal 
muscle contraction (Bredt 1999). eNOS is bound to the Golgi apparatus of endothelial 
cells, where it regulates vascular reactivity in the 
periphery and brain (Deckel 2001). Activation is primarily brought about by Ca2+ fluxes 
and subsequent binding of the calcium regulatory protein – calmodulin (Bogdan 2001). 
The third isoform of NOS is referred to as inducible NOS (iNOS). It is not normally 
expressed under physiological conditions but, stimulation by pro-inflammatory 
mediators, such as cytokines or endotoxin, cause its rapid formation (Bredt 1999). One 
of the distinguishing features of this isoform is that it does not require an increase in 
cellular Ca2+  levels to become activated (Deckel 2001). Activation of iNOS leads to the 
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production of micromolar levels of NO, much higher than the nanomolar levels 
generated by the constitutive eNOS and nNOS (Achike and Kwan 2003). Prolonged 
exposure to a large amount of NO can inhibit the activity of several enzymes, such as 
aconitase and cytochrome c oxidase, resulting in potential cytotoxicity and the 
development of pathogenesis (Nathan and Hibbs 1991). It is these pathogenic 
responses to NO and the pathways underlying them, which shall form the basis of this 
review. The possible functions of the different NOS isoforms within immune cells will be 
examined and the mechanisms behind the regulation of NOS activity shall be explored. 
NO production in the immune system and mechanisms of its 
regulation 
The generation of NO is a key feature of many immune cells, including dendritic cells, 
NK cells, mast cells, macrophages and other phagocytic cells. Either iNOS or eNOS 
has been found in all of these cell types but the evidence remains uncertain as to 
whether primary T or B lymphocytes express the NOS isoforms (Bogdan 2001). This is 
an area to which further research could be targeted, to clarify the contradicting results 
gained through other studies. Previous work carried out by Relling (1996) relied solely 
on PCR methods to detect NOS mRNA within T cells, increasing the possibility of false 
positives, through the contamination of other cells. Much focus within previous research 
has been placed upon the classical phagocytic cells, such as macrophages, examining 
the role they play in NO production. There seems to be much less information regarding 
T and B lymphocytes and the position that they hold with respect to the expression of 
NOS. 
All three isoforms of NOS are regulated at various levels during an immune response. 
They have similar regulation processes however, because eNOS and nNOS are 
preformed within the cell, their activity can be switched on by Ca2+  level increases and 
calmodulin, as previously explained. In contrast, iNOS mRNA has to be synthesised 
under the appropriate stimuli and the gene promoter for this provides a mode of 
regulation under the influence of cytokines (Pellacani et al. 2001). Some of the 
participating transcription factors include NF-ĸB, AP-1 and STAT-1α. Depending on the 
microbial or cytokine stimulus, different upstream signalling pathways are involved 
which either promote or inhibit iNOS expression. The NF-ĸB is present in an inactive 
form in the cytosol as a complex with IkB. When an inducer, such as LPS, stimulates 
the cell, the IkB- NF-ĸB complex is phosphorylated, allowing the NF-ĸB to translocate to 
the nucleus and induce iNOS gene expression (Aktan 2004). Supportive studies carried 
out by Musial and Eissa (2001) found that some compounds were also able to suppress 
iNOS induction by blocking IkB degradation.  NO production itself can regulate its own 
production, as was described by Connelly et al. (2001). He showed that upon initial 
macrophage stimulation by cytokines, when the NO concentrations were low, NFĸB was 
upregulated and further iNOS was produced (positive feedback). Under high NO 
conditions, the opposite phenomena was observed. This negative feedback could be a 
mechanism to help prevent the overproduction of NO and the associated pathologies. In 
a similar study conducted by Perez-Sala et al. (2001), the biphasic effect of NO 
synthesis was shown to be mediated through the inhibition of NFĸB. This regulatory site 
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within the signalling pathway could be investigated further as a potential intervention 
point for therapies associated with inflammatory diseases. 
Many of the studies investigated for this review used a combination of LPS and IFNγ to 
stimulate immune cells, such as macrophages, to produce NO. This is because certain 
combinations of cytokines or LPS with IFNγ are able to induce iNOS expression 
synergistically (Chong et al. 2002). They signal through the Jak-STAT pathway, where 
STAT1 becomes activated and translocates to the nucleus, increasing IRF-1 levels and 
ultimately inducing iNOS (Aktan 2004).  
NO, leukocyte adhesion and chemotaxis 
Various studies have shown that NO inhibits the adhesion of platelets and leukocytes to 
endothelium and also significantly impeding their rolling and transmigration (Grisham et 
al. 1998). Both Grisham et al (1998) and Bogdan (2001) used monocytes and 
granulocytes with a monolayer of endothelial cells. They performed the experiments 
using flow chambers and endogenously produced NO in addition to NO from donors. 
Both independent studies came to the same conclusions; that the NO was indeed acting 
to inhibit the adhesion of the leukocytes. The methods behind this inhibition were not 
explored within these studies and there also seems to be a lack of published literature 
to explain these mechanisms. The possible effects that NO could exert on the adhesion 
of other immune cells, such as T and B lymphocytes also proved difficult to find within 
any of the papers researched. This is an area to which further investigations and studies 
could be targeted to gain a deeper insight into this feature of NO. The chemotaxis of 
leukocytes has however been demonstrated, within several studies, to be influenced by 
NO. Bogdan (2000) showed that it can modulate chemokine production, such as IP-10 
and monocyte chemoattractant protein-1. In addition to this, Cheria and Garu (2001) 
showed that NO was able to inhibit the activity of chemokines, such as IL8, and to 
function as an intracellular messenger in chemokine signalling pathways.   
NO and the thymus 
The thymus has a central role in immunology, as it is the place where T cells diversify 
and differentiate by positive and negative selection processes (Goldsby et al. 2003). 
Those cells which respond too strongly to self-MHC are induced to die through 
apoptosis, thereby preventing autoimmunity. Because of NO’s capacity to induce 
apoptosis, many scientists have investigated its possible role within the thymus, acting 
to assist in correct T cell development. In a study by Allello et al (2000), human 
thymocytes were found to be lacking the iNOS protein. However, epithelial and dendritic 
cells within the medulla and corticomedullary junction were shown to constitutively 
express iNOS and this was further upregulated upon contact with self antigens. 
Developing on the ideas presented by Allello et al (2000), Moullan (2001) and his team 
discovered that TCR-activated double-positive thymocytes were particularly sensitive to 
killing by NO. These combined data strongly suggest that NO, released by iNOS 
expressing cells within the thymus, contributes to the deletion of double-positive 
thymocytes.  
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NO in infection and inflammation 
NO plays a crucial role at all stages of infection and it has a diverse and somewhat 
contradictory spectrum of activities. Rollinghoff et al. (2000) used iNOS-/- mice in their 
informative study, concluding that a vast array of immunological effects are indeed 
mediated by NO. The functions of NO which they described were; antiviral, 
antimicrobial, immunostimulatory, immunosuppressive, cytotoxic and cytoprotective.  
The antimicrobial powers of NO are thought to occur through several mechanisms 
including, mutation of DNA, inhibition of DNA repair and synthesis, alteration of proteins 
and inactivation of enzymes (Bogdan 2001).  Further iNOS-dependent protective effects 
during infection include the inhibition of tissue fibrosis and the termination of the 
immune response by apoptosis of activated CD4+ T cells (Dalton et al. 2000). The in 
vitro killing via NO of Mycobacterium avium-intracellulare and Leishmania major by 
activated macrophages was shown in the studies by Kronck et al (1998). This notion 
was developed further by Iniesta et al (2001). Their study suggested that Nω-hydroxy-L-
arginine, an intermediate of the L-argine-iNOS-NO pathway, contributes to the killing of 
intracellular Leischmania by blocking arginase activity within the parasite and the 
macrophage. This compares similarly to the outcome of an additional study, where 
Leischmania major-infected mice were treated with the NOS inhibitor NMMA, resulting 
in substantially increased parasite loads and the development of larger skin legions, 
validating the importance of this mechanism in regulating parasite growth in vivo 
(Gobert et al. 2000).  
It has also been found that the antimicrobial activity of NO may be mediated by indirect 
effects. One type of infectious pathogen, African trypanosomes, along with many others, 
are dependent on exogenous arginine for the production of polyamines and cell 
proliferation. Bryk et al (2000) used these pathogens in their experiments to show that 
when arginine levels become depleted by the induction of iNOS, it can result in the 
growth inhibition, or death of the parasite.  
A good indication for the defence role of NO at the interface between the body and the 
external environment, has been demonstrated on the surface of the tongue, in a dated 
but interesting study by Benjamin et al (1994).  They demonstrated the fact that in the 
mouth, facultative anaerobic bacteria reduce nitrate within the saliva rapidly to nitrite. 
When this is swallowed, large amounts of NO are generated in the stomach, partly due 
to the acidic conditions. Similar studies have also been carried out, which show that NO 
is continuously released from the skin’s surface (Weller et al 1996). Within this research 
by Weller et al (1996), commensal bacteria was shown to reduce the nitrate present 
within sweat to nitrite where it was then reduced further, forming NO -again due to the 
acidic conditions on the surface of the skin. Although the studies mentioned here are 
fairly dated, they provide a valuable insight into a further defensive role that NO plays 
within the immune system, outside of the more obvious roles and features of this multi-
functional gas molecule. 
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In addition to the beneficial effects that NO exerts when the body is challenged with 
infection, it is also known to display pathogenic properties when sustained at high 
concentrations (Aktan 2004). NO can, under certain circumstances, mediate cytotoxicity 
and tissue damage, inhibit T cell proliferation, induce T cell apoptosis, generate viral 
escape mutants and also have direct positive effects on viral or microbial growth 
(Bogdan 2001). When NO is produced in large amounts by myeloid cells, it is generated 
also with equally large amounts of superoxide anion (O2
-). These two compounds can 
then form peroxynitrite (ONOO-), which is a mediator of the cytotoxic effects of NO 
(Guzik 2003). The production of ONOO-, NO. and other reactive oxidising compounds in 
the presence of superoxide radicals or peroxidises, can cause the reversal of NO 
effects from protective to deleterious (Aktan 2004). These products can target 
numerous proteins and enzymes which are critical for cell survival and signalling; 
nitrating cysteines within their structures, leading to their activation or inactivation 
(Coleman 2001). Such toxic effects of NO have been 
studied and are shown to underlie the pathogenesis of septic shock. Thiemermann 
(1997) indicated that increased amounts of nitric oxide (as occurs during endotoxic or 
cytokine-induced shock) contribute to excessive vasodilation, resulting in a decrease in 
vascular tone and a fall in blood pressure. The plasma NO concentrations in patients 
with septic shock were shown to be hugely increased and the administration of a 
specific NOS inhibitor was able to increase the blood pressure but with side effects. A 
study carried out Parrett (2000) also found that the use of NOS inhibitors as a treatment 
for septic shock produced a detrimental side effect of decreased cardiac output. 
Several research papers have been produced from the results of investigative work into  
the field of NO and its role in inflammatory pathologies. It can occasionally become part 
of a dysregulated immune response, resulting in chronic inflammatory disorders.  
In recent years, NO has become associated with the initiation and maintenance of 
inflammatory bowel disease. In a study carried out by Boughton-Smith et al (1994) 
rectal biopsy sections were examined from patients with active ulcerative colitis (UC). 
The results showed that citrulline concentrations (the co-product of NO synthase) were 
much higher in the biopsies from UC sufferers than in those with normal histology. 
Incubating the biopsy samples with L-NMMA, an inhibitor of NOS, significantly reduced 
the citrulline concentrations, therefore indicating that the increase must be as a result of 
NOS activity (Boughton-Smith et al 1994). Kolios et al (2004) found similar results when 
studies were undertaken using patients with both UC and Crohn’s disease (CD). The 
colonic mucosa of the patients’ biopsies showed iNOS activity eightfold higher than in 
the control subject’s mucosa.  
These results, along with those of countless other studies show a definite link between 
the up-regulation of iNOS and the clinicopathological features found in many chronic 
IBDs. The excessive concentrations of NO may exacerbate the features of these 
pathologies by direct cytotoxicity, vasodilation, activation of neutrophils and by the 
formation of the highly toxic peroxynitrite radical (Kolios et al 2004). 
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NO and tumours 
NO’s involvement with tumour development seems extremely complex and some what 
contradictory. It has both tumouricidal effects and, more recently discovered, deleterious 
tumour-promoting effects. Macrophage-derived NO can cause cytostasis or kill tumour 
cells in vitro (Bogdan 2001). Kroncke et al (1998) found that iNOS protein could be 
detected in the vasculature, infiltrating macrophages and the tumour cells of human 
brain, breast, lung and colon tumours. He revealed that the NO produced by the tumour 
itself could potentially inhibit proliferation or induce apoptosis of T cells, which would in 
turn suppress the host’s immune system. In contrast to this, a study performed by Kwak 
et al (2000), found that tumour cell death could be achieved by the induction of iNOS 
within the tumour cells. This iNOS was stimulated in response to IFNγ and TNF, which 
was released by cytotoxic lymphocytes. This evidence seems to imply that the tumour 
cells can use nitric oxide for their own advantage but at the same time, it can be 
targeted against the tumour to assist in its destruction. Further research by Xu et al 
(2000) confirmed that the iNOS expressed by the tumour is able to promote its growth, 
neovascularisation and invasiveness, by the induction of p53 mutations and the 
upregulation of VEGF (vascular endothelial growth factor). He also found that by 
exposing the tumour cells to NO, there was an upregulation of the catalytic subunit of 
the DNA-dependent protein kinase - essential for repairing DNA breaks. This important 
discovery suggests that the tumour cells could be protected from the potential toxic 
effects exerted by NO but also protected from the therapeutic agents used to treat the 
tumour. As suggested by Bogdan (2001), NO-based strategies intended for use as a 
tumour treatment, must take into account the results gained within these and other such 
studies. 
There is much research which suggests the involvement of NO in the carcinogenesis of 
some cases of breast carcinoma (Gatti et al 2003). A study by Umansky and 
Schirrmacher (2001) used a human tumour cell line transfected for constitutive 
expression of iNOS to investigate this theory. They found that the cells showed 
increased growth rate, vascular density and micro-invasiveness. Supporting these 
observations were the results of a further study, by Harmey et al (2002) where benign 
and malignant breast cancer tissues were compared for levels of NOS activity. The 
benign tissues had NOS levels below that of detection whereas the levels were 
continually elevated within the malignant tissues. Loibl et al (2002) also came to similar 
conclusions when they carried out assays and discovered that the detection of iNOS 
within benign breast lesions was extremely rare. 
NO and neurodegenerative diseases 
Parkinson’s and Alzheimer’s diseases are both neurodegenerative conditions that are 
associated with oxidative stress, resulting from mitochondrial dysfunction and the 
production of ROS (Achike and Kwan 2003). Neuronal damage in these diseases has 
been linked to an increase in nNOS and NO production (Hantraye et al 1996). iNOS is 
also believed to be involved in the pathogenesis, due to its activation within astrocytes, 
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by the β-amyloid peptide (characteristic of the amyloid plaques) (Achike and Kwan 
2003). Supportive conclusions can be found within a study carried out by Achike and 
Kwan (2003). Post-mortem specimens of brain tissue were analysed and it was found 
that iNOS expression was high in the demyelinated regions of the brain. 
Conclusions 
In summary of this review of literature, nitric oxide has been shown to have diverse 
biological functions and effects within the immune system. It is an intra- and intercellular 
signalling molecule that can shape the immune response and sustain homeostasis. NO 
is a potent anti-microbial defender and has many host-protective effects that are most 
evident during invasion by infectious agents. It also has a possible role in thymic 
selection processes and the regulation of T cell differentiation. However, in contrast to 
these beneficial roles, NO has been shown to have the potential to switch from being an 
indispensable regulator to a harmful destroyer. The overstimulation of NOS can assist 
with disease generation, inflammatory pathologies, neurodegenerative diseases and 
also cancer progression.  
Within the scope and limitations of this review, only a brief overview could be given of 
the relationship between nitric oxide and the immune system. It covers such a broad 
and detailed area that it would be beneficial to dissect the research down much further, 
allowing the in-depth analysis of just one specific factor, such as NO and inflammation 
or cancer. The field of immunology is dynamic and exciting with new discoveries and 
theories constantly being developed. Further informative research into the fascinating 
nitric oxide molecule shall no doubt be only a short time away. 
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